Therapy From a Novel Substernal Lead: The ASD2 Study

Lucas V.A. Boersma, B. Merkely, Petr Neuzil, Ian G. Crozier, Devender N. Akula, Liesbeth Timmers, Zbigniew Kalarus, Lou Sherfesee, Paul J. DeGroot, Amy E. Thompson, Daniel R. Lexcen, Bradley P. Knight

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objectives: The ASD2 (Acute Extravascular Defibrillation, Pacing, and Electrogram) study evaluated the ability to adequately sense, pace, and defibrillate patients with a novel implantable cardioverter-defibrillator (ICD) lead implanted in the substernal space. Background: Subcutaneous ICDs are an alternative to a transvenous defibrillator system when transvenous implantation is not possible or desired. An alternative extravascular system placing a lead under the sternum has the potential to reduce defibrillation energy and the ability to deliver pacing therapies. Methods: An investigational lead was inserted into the substernal space via a minimally invasive subxiphoid access, and a cutaneous defibrillation patch or subcutaneous active can emulator was placed on the left mid-axillary line. Pacing thresholds and extracardiac stimulation were evaluated. Up to 2 episodes of ventricular fibrillation were induced to test defibrillation efficacy. Results: The substernal lead was implanted in 79 patients, with a median implantation time of 12.0 ± 9.0 min. Ventricular pacing was successful in at least 1 vector in 76 of 78 patients (97.4%), and 72 of 78 (92.3%) patients had capture in ≥1 vector with no extracardiac stimulation. A 30-J shock successfully terminated 104 of 128 episodes (81.3%) of ventricular fibrillation in 69 patients. There were 7 adverse events in 6 patients causally (n = 5) or possibly (n = 2) related to the ASD2 procedure. Conclusions: The ASD2 study demonstrated the ability to pace, sense, and defibrillate using a lead designed specifically for the substernal space.

Original languageEnglish
Pages (from-to)186-196
Number of pages11
JournalJACC: Clinical Electrophysiology
Volume5
Issue number2
DOIs
Publication statusPublished - Feb 1 2019

Fingerprint

Ventricular Fibrillation
Therapeutics
Sternum
Defibrillators
Implantable Defibrillators
Lead
Shock
Skin

Keywords

  • anterior mediastinum
  • defibrillation lead
  • extravascular
  • implantable cardioverter-defibrillator
  • substernal
  • tachyarrhythmia

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Boersma, L. V. A., Merkely, B., Neuzil, P., Crozier, I. G., Akula, D. N., Timmers, L., ... Knight, B. P. (2019). Therapy From a Novel Substernal Lead: The ASD2 Study. JACC: Clinical Electrophysiology, 5(2), 186-196. https://doi.org/10.1016/j.jacep.2018.11.003

Therapy From a Novel Substernal Lead : The ASD2 Study. / Boersma, Lucas V.A.; Merkely, B.; Neuzil, Petr; Crozier, Ian G.; Akula, Devender N.; Timmers, Liesbeth; Kalarus, Zbigniew; Sherfesee, Lou; DeGroot, Paul J.; Thompson, Amy E.; Lexcen, Daniel R.; Knight, Bradley P.

In: JACC: Clinical Electrophysiology, Vol. 5, No. 2, 01.02.2019, p. 186-196.

Research output: Contribution to journalArticle

Boersma, LVA, Merkely, B, Neuzil, P, Crozier, IG, Akula, DN, Timmers, L, Kalarus, Z, Sherfesee, L, DeGroot, PJ, Thompson, AE, Lexcen, DR & Knight, BP 2019, 'Therapy From a Novel Substernal Lead: The ASD2 Study', JACC: Clinical Electrophysiology, vol. 5, no. 2, pp. 186-196. https://doi.org/10.1016/j.jacep.2018.11.003
Boersma, Lucas V.A. ; Merkely, B. ; Neuzil, Petr ; Crozier, Ian G. ; Akula, Devender N. ; Timmers, Liesbeth ; Kalarus, Zbigniew ; Sherfesee, Lou ; DeGroot, Paul J. ; Thompson, Amy E. ; Lexcen, Daniel R. ; Knight, Bradley P. / Therapy From a Novel Substernal Lead : The ASD2 Study. In: JACC: Clinical Electrophysiology. 2019 ; Vol. 5, No. 2. pp. 186-196.
@article{d717e5a30c7145b0905ea3cdb9e7a83b,
title = "Therapy From a Novel Substernal Lead: The ASD2 Study",
abstract = "Objectives: The ASD2 (Acute Extravascular Defibrillation, Pacing, and Electrogram) study evaluated the ability to adequately sense, pace, and defibrillate patients with a novel implantable cardioverter-defibrillator (ICD) lead implanted in the substernal space. Background: Subcutaneous ICDs are an alternative to a transvenous defibrillator system when transvenous implantation is not possible or desired. An alternative extravascular system placing a lead under the sternum has the potential to reduce defibrillation energy and the ability to deliver pacing therapies. Methods: An investigational lead was inserted into the substernal space via a minimally invasive subxiphoid access, and a cutaneous defibrillation patch or subcutaneous active can emulator was placed on the left mid-axillary line. Pacing thresholds and extracardiac stimulation were evaluated. Up to 2 episodes of ventricular fibrillation were induced to test defibrillation efficacy. Results: The substernal lead was implanted in 79 patients, with a median implantation time of 12.0 ± 9.0 min. Ventricular pacing was successful in at least 1 vector in 76 of 78 patients (97.4{\%}), and 72 of 78 (92.3{\%}) patients had capture in ≥1 vector with no extracardiac stimulation. A 30-J shock successfully terminated 104 of 128 episodes (81.3{\%}) of ventricular fibrillation in 69 patients. There were 7 adverse events in 6 patients causally (n = 5) or possibly (n = 2) related to the ASD2 procedure. Conclusions: The ASD2 study demonstrated the ability to pace, sense, and defibrillate using a lead designed specifically for the substernal space.",
keywords = "anterior mediastinum, defibrillation lead, extravascular, implantable cardioverter-defibrillator, substernal, tachyarrhythmia",
author = "Boersma, {Lucas V.A.} and B. Merkely and Petr Neuzil and Crozier, {Ian G.} and Akula, {Devender N.} and Liesbeth Timmers and Zbigniew Kalarus and Lou Sherfesee and DeGroot, {Paul J.} and Thompson, {Amy E.} and Lexcen, {Daniel R.} and Knight, {Bradley P.}",
year = "2019",
month = "2",
day = "1",
doi = "10.1016/j.jacep.2018.11.003",
language = "English",
volume = "5",
pages = "186--196",
journal = "JACC: Clinical Electrophysiology",
issn = "2405-5018",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Therapy From a Novel Substernal Lead

T2 - The ASD2 Study

AU - Boersma, Lucas V.A.

AU - Merkely, B.

AU - Neuzil, Petr

AU - Crozier, Ian G.

AU - Akula, Devender N.

AU - Timmers, Liesbeth

AU - Kalarus, Zbigniew

AU - Sherfesee, Lou

AU - DeGroot, Paul J.

AU - Thompson, Amy E.

AU - Lexcen, Daniel R.

AU - Knight, Bradley P.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Objectives: The ASD2 (Acute Extravascular Defibrillation, Pacing, and Electrogram) study evaluated the ability to adequately sense, pace, and defibrillate patients with a novel implantable cardioverter-defibrillator (ICD) lead implanted in the substernal space. Background: Subcutaneous ICDs are an alternative to a transvenous defibrillator system when transvenous implantation is not possible or desired. An alternative extravascular system placing a lead under the sternum has the potential to reduce defibrillation energy and the ability to deliver pacing therapies. Methods: An investigational lead was inserted into the substernal space via a minimally invasive subxiphoid access, and a cutaneous defibrillation patch or subcutaneous active can emulator was placed on the left mid-axillary line. Pacing thresholds and extracardiac stimulation were evaluated. Up to 2 episodes of ventricular fibrillation were induced to test defibrillation efficacy. Results: The substernal lead was implanted in 79 patients, with a median implantation time of 12.0 ± 9.0 min. Ventricular pacing was successful in at least 1 vector in 76 of 78 patients (97.4%), and 72 of 78 (92.3%) patients had capture in ≥1 vector with no extracardiac stimulation. A 30-J shock successfully terminated 104 of 128 episodes (81.3%) of ventricular fibrillation in 69 patients. There were 7 adverse events in 6 patients causally (n = 5) or possibly (n = 2) related to the ASD2 procedure. Conclusions: The ASD2 study demonstrated the ability to pace, sense, and defibrillate using a lead designed specifically for the substernal space.

AB - Objectives: The ASD2 (Acute Extravascular Defibrillation, Pacing, and Electrogram) study evaluated the ability to adequately sense, pace, and defibrillate patients with a novel implantable cardioverter-defibrillator (ICD) lead implanted in the substernal space. Background: Subcutaneous ICDs are an alternative to a transvenous defibrillator system when transvenous implantation is not possible or desired. An alternative extravascular system placing a lead under the sternum has the potential to reduce defibrillation energy and the ability to deliver pacing therapies. Methods: An investigational lead was inserted into the substernal space via a minimally invasive subxiphoid access, and a cutaneous defibrillation patch or subcutaneous active can emulator was placed on the left mid-axillary line. Pacing thresholds and extracardiac stimulation were evaluated. Up to 2 episodes of ventricular fibrillation were induced to test defibrillation efficacy. Results: The substernal lead was implanted in 79 patients, with a median implantation time of 12.0 ± 9.0 min. Ventricular pacing was successful in at least 1 vector in 76 of 78 patients (97.4%), and 72 of 78 (92.3%) patients had capture in ≥1 vector with no extracardiac stimulation. A 30-J shock successfully terminated 104 of 128 episodes (81.3%) of ventricular fibrillation in 69 patients. There were 7 adverse events in 6 patients causally (n = 5) or possibly (n = 2) related to the ASD2 procedure. Conclusions: The ASD2 study demonstrated the ability to pace, sense, and defibrillate using a lead designed specifically for the substernal space.

KW - anterior mediastinum

KW - defibrillation lead

KW - extravascular

KW - implantable cardioverter-defibrillator

KW - substernal

KW - tachyarrhythmia

UR - http://www.scopus.com/inward/record.url?scp=85061124512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061124512&partnerID=8YFLogxK

U2 - 10.1016/j.jacep.2018.11.003

DO - 10.1016/j.jacep.2018.11.003

M3 - Article

C2 - 30784689

AN - SCOPUS:85061124512

VL - 5

SP - 186

EP - 196

JO - JACC: Clinical Electrophysiology

JF - JACC: Clinical Electrophysiology

SN - 2405-5018

IS - 2

ER -